Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Impax Laboratories, Inc
WARNING LETTER
•Impax Laboratories, Inc•January 21, 2011

Impax Laboratories, Inc – FDA Warning Letter, Jan 21, 2011

Record Details

The FDA issued a Warning Letter to Impax Laboratories, Inc. following a December 2010 to January 2011 inspection of their Hayward, CA pharmaceutical manufacturing facility. The inspection revealed significant Current Good Manufacturing Practice (CGMP) violations under 21 CFR Parts 210 and 211, rendering their drug products adulterated per 21 U.S.C. § 351(a)(2)(B). The firm's February 2011 response was deemed insufficient. Key violations include the failure to establish written procedures for monitoring and validating manufacturing processes responsible for variability in in-process material and drug product, specifically regarding Fenofibrate 200mg capsule weight variations and unsupported temperature ranges for Colestipol Hydrochloride 1g tablet granulation (21 CFR § 211.110(a)). Additionally, the firm failed to thoroughly investigate batch failures, such as widespread metal contamination in various drug products, and extend investigations to other affected batches (21 CFR § 211.192). This latter issue was a repeat observation, indicating ineffective corrective actions. Impax Laboratories must promptly correct these violations. They are required to provide a written response within fifteen working days detailing specific corrective steps, preventative measures, and supporting documentation. Failure to comply may result in legal actions like seizure and injunction, impact federal contracts, and lead to the withholding of export certificates or denial of pending drug applications. FDA will re-inspect to verify corrections.

Company
Impax Laboratories, Inc
Inspection date
January 21, 2011
Product type
Drugs
Office
San Francisco District Office
People
  • Barbara J. Cassens (Director )
  • Darlene B. Almogela
  • Carl Lee
View Company Profile

ID · a931ca68-4545-4dad-9ce3-ed3d5f874126

Violation Codes6
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.110(a)21 CFR 211.192FD&C Act 501(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Impax Laboratories, Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.